Abdominal aortic aneurysm - Inflammation - Cardiovascular diseases - Metalloproteinases - Doxycycline - Pharmaceutical Treatment
Conditions
Interventions
Doxycycline 100mg or placebo daily, 18 mo
Sponsors
Nuts Ohra
Eligibility
Inclusion criteria
Inclusion criteria: Patients under surveillance with small aneurysms (i.e. 3.5-5.0 cm), and in larger AAA in patients who are unfit for or refuse open operation or endovascular intervention of their larger AAA (i.e. exceeding 5.0 cm).
Exclusion criteria
Exclusion criteria: 1. Unable to comply with follow up. 2. Contra-indications for doxycycline: - known impaired liver function (ALAT >3-fold normal values) - known renal failure (estimate clearance below 40 ml/min) - excessive sun exposure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * Aneurysm growth at t=18 months as determined by ultrasound | — |
Secondary
| Measure | Time frame |
|---|---|
| * Secondary outcome measures are: - growth at 6 and 12 months - need for elective aneurysm repair - rupture - death - an inventory of possible side effects (questionnaire). Moreover, posible effect on atherosclerosis will be evaluated by: - assesment of intima media thickness (carotid artery) - plasma inflmmatory markers - endothelial cell markers - spirometric testing. | — |
Contacts
Public ContactJan H. Lindeman
Leiden University Medical Center Dpt. of Vascular Surgery. PO-box 9600
Outcome results
None listed